As of November 6, 2026, 4 holders' latest Schedule 13D or 13G filings report owning 5% or more of Sana Biotechnology Inc. The largest reported stake is Robert Nelsen's, at 15.4%. 5 filings are on record since November 14, 2025 (Schedule 13G/A, August 14, 2026).
Sell to companies like Sana Biotechnology Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · Reporting person: Fmr LLC · Sole voting: 37,292,259 · Shared voting: 0 · Sole dispositive: 37,293,854 · Shared dispositive: 0 · SCHEDULE 13G/A, 2026-11-05
- · Reporting person: ARCH Venture Fund IX, L.P. · Sole voting: 0 · Shared voting: 45,860,681 · Sole dispositive: 0 · Shared dispositive: 45,860,681 · SCHEDULE 13G/A, 2026-08-14
- · Reporting person: RA Capital Management, L.P. · Sole voting: 0 · Shared voting: 18,750,000 · Sole dispositive: 0 · Shared dispositive: 18,750,000 · SCHEDULE 13G, 2026-05-21
- · Reporting person: BlackRock, Inc. · Sole voting: 13,405,747 · Shared voting: 0 · Sole dispositive: 13,643,304 · Shared dispositive: 0 · SCHEDULE 13G, 2026-01-21
- · Holder: Robert Nelsen · Percent: 17.3% · SCHEDULE 13G/A
Sana Biotechnology Inc has 5 Schedule 13D or 13G filings on record since 2025-11-14. 4 holders' latest filing reports 5% or more of common stock. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| 15.4% | 46,173,125 | SCHEDULE 13G/A, 2026-08-14 | 2026-06-30 | |
| Fmr LLC | 12.5% | 37,293,854 | SCHEDULE 13G/A, 2026-11-05 | 2026-09-30 |
| RA Capital Management, L.P. | 6.3% | 18,750,000 | SCHEDULE 13G, 2026-05-21 | 2026-05-14 |
| BlackRock, Inc. | 5.1% | 13,643,304 | SCHEDULE 13G, 2026-01-21 | 2025-12-31 |
Holding shares or following this stake? See who's behind Sana Biotechnology Inc and the warning signs.
Free to see. No signup.
Keep reading
More on Sana Biotechnology Inc and the records around it.
Sana Biotechnology Inc elsewhere on the record
- Leadership changes Apr 2026
- Who owns it
Companies that share a holder
- ARCH Venture Fund IX, L.P. also filed stake reports on 2 other companies: Vir Biotechnology, Inc. (Nov 2026), Lyell Immunopharma, Inc. (May 2026)
- RA Capital Management, L.P. also filed stake reports on 100 other companies: Climb Bio, Inc. (Nov 2026), Bambusa Therapeutics, Inc. (Nov 2026), SOLID BIOSCIENCES INC. (Nov 2026)
- FMR LLC also filed stake reports on 761 other companies: ASPEN NEUROSCIENCE INC (Nov 2026), AVALO THERAPEUTICS INC (Nov 2026), BRAZE INC (Nov 2026)
Watch Sana Biotechnology Inc
Get an email when Sana Biotechnology Inc files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Sana Biotechnology Inc?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Sana Biotechnology Inc: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Sana Biotechnology Inc covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
6 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Voting and dispositive power, as filed
| Reporting person | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Filing |
|---|---|---|---|---|---|
| ARCH Venture Fund IX, L.P. | 0 | 45,860,681 | 0 | 45,860,681 | SCHEDULE 13G/A, 2026-08-14 |
| ARCH Venture Fund IX Overage, L.P. | 0 | 45,860,681 | 0 | 45,860,681 | SCHEDULE 13G/A, 2026-08-14 |
| ARCH Venture Fund X, L.P. | 0 | 45,860,681 | 0 | 45,860,681 | SCHEDULE 13G/A, 2026-08-14 |
| ARCH Venture Fund X Overage, L.P. | 0 | 45,860,681 | 0 | 45,860,681 | SCHEDULE 13G/A, 2026-08-14 |
| ARCH Venture Partners IX, L.P. | 0 | 45,860,681 | 0 | 45,860,681 | SCHEDULE 13G/A, 2026-08-14 |
| ARCH Venture Partners IX Overage, L.P. | 0 | 45,860,681 | 0 | 45,860,681 | SCHEDULE 13G/A, 2026-08-14 |
| ARCH Venture Partners X Overage, L.P. | 0 | 45,860,681 | 0 | 45,860,681 | SCHEDULE 13G/A, 2026-08-14 |
| ARCH Venture Partners X, L.P. | 0 | 45,860,681 | 0 | 45,860,681 | SCHEDULE 13G/A, 2026-08-14 |
| ARCH Venture Partners IX, LLC | 0 | 45,860,681 | 0 | 45,860,681 | SCHEDULE 13G/A, 2026-08-14 |
| ARCH Venture Partners X, LLC | 0 | 45,860,681 | 0 | 45,860,681 | SCHEDULE 13G/A, 2026-08-14 |
| Keith Crandell | 0 | 45,860,681 | 0 | 45,860,681 | SCHEDULE 13G/A, 2026-08-14 |
| Clinton Bybee | 0 | 45,860,681 | 0 | 45,860,681 | SCHEDULE 13G/A, 2026-08-14 |
| Robert Nelsen | 312,444 | 45,860,681 | 312,444 | 45,860,681 | SCHEDULE 13G/A, 2026-08-14 |
| Steven Gillis | 0 | 45,860,681 | 0 | 45,860,681 | SCHEDULE 13G/A, 2026-08-14 |
| Kristina Burow | 0 | 45,860,681 | 0 | 45,860,681 | SCHEDULE 13G/A, 2026-08-14 |
| Fmr LLC | 37,292,259 | 0 | 37,293,854 | 0 | SCHEDULE 13G/A, 2026-11-05 |
| Abigail P. Johnson | 0 | 0 | 37,293,854 | 0 | SCHEDULE 13G/A, 2026-11-05 |
| RA Capital Management, L.P. | 0 | 18,750,000 | 0 | 18,750,000 | SCHEDULE 13G, 2026-05-21 |
| Peter Kolchinsky | 0 | 18,750,000 | 0 | 18,750,000 | SCHEDULE 13G, 2026-05-21 |
| Rajeev Shah | 0 | 18,750,000 | 0 | 18,750,000 | SCHEDULE 13G, 2026-05-21 |
| RA Capital Healthcare Fund, L.P. | 0 | 18,750,000 | 0 | 18,750,000 | SCHEDULE 13G, 2026-05-21 |
| BlackRock, Inc. | 13,405,747 | 0 | 13,643,304 | 0 | SCHEDULE 13G, 2026-01-21 |
The latest filing identifies Sana Biotechnology Inc by CUSIP 799566104 and gives its principal executive office as 188 EAST BLAINE STREET, SUITE 350, SEATTLE, WA 98102 (SCHEDULE 13G/A, 2026-11-05).
What the percentages are based on
The information required by Item 4(b) is incorporated by reference to Row 11 of the cover pages hereto.Robert Nelsen, SCHEDULE 13G/A, 2026-08-14
Row 11 of each Reporting Person's cover page to this Schedule 13G sets forth the percentages of shares of common stock of the Issuer beneficially owned by such Reporting Person and is incorporated by reference.RA Capital Management, L.P., SCHEDULE 13G, 2026-05-21
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-11-14 | Robert Nelsen | 17.3% | SCHEDULE 13G/A |
| 2026-01-21 | BlackRock, Inc. | 5.1% | SCHEDULE 13G |
| 2026-05-21 | RA Capital Management, L.P. | 6.3% | SCHEDULE 13G |
| 2026-08-14 | Robert Nelsen | 15.4% | SCHEDULE 13G/A |
| 2026-11-05 | Fmr LLC | 12.5% | SCHEDULE 13G/A |
Questions about who owns Sana Biotechnology Inc
Who owns Sana Biotechnology Inc?
On this page, 4 holders' latest ownership filings report 5% or more of Sana Biotechnology Inc: Robert Nelsen (15.4%, Schedule 13G/A, filed 2026-08-14), Fmr LLC (12.5%, Schedule 13G/A, filed 2026-11-05), RA Capital Management, L.P. (6.3%, Schedule 13G, filed 2026-05-21) and BlackRock, Inc. (5.1%, Schedule 13G, filed 2026-01-21).
Who are the largest shareholders of Sana Biotechnology Inc?
By the share each holder's latest filing reports, the largest holders of Sana Biotechnology Inc on this page are Robert Nelsen (15.4%), Fmr LLC (12.5%) and RA Capital Management, L.P. (6.3%).
When did Robert Nelsen buy into Sana Biotechnology Inc?
The filings give report dates, not purchase dates. The earliest filing from Robert Nelsen on this page is the Schedule 13G/A, filed 2025-11-14, reporting 17.3%; its latest, Schedule 13G/A filed 2026-08-14, reports 15.4%. That earliest filing is itself an amendment, which updates an earlier report.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 5 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Also on the record for Sana Biotechnology Inc
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| April 24, 2026 | Leadership change: Steven D. Harr departs, Director | — | Leadership changes | Source |
Tools for this story
Each opens in a new tab, filled in for Sana Biotechnology Inc. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.